Han Zhao
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Han Zhao has a total of 24 co-authors. Here are the top co-authors by number of shared publications:
- Guiping Ren
Biopharmaceutical Lab, College of Life Science, Northeast Agricultural University, Harbin 150030, China; Research Center of Genetic Engineering of Pharmaceuticals of Heilongjiang Province, Northeast Agricultural University, Harbin 150030, China; Key Laboratory of Agricultural Biological Functional Gene, Northeast Agricultural University, Harbin 150030, China
2 shared publications - Jiechao Yin
Biopharmaceutical Lab, College of Life Science, Northeast Agricultural University, Harbin 150030, China
2 shared publications - Lan Wei
Biopharmaceutical Lab, College of Life Science, Northeast Agricultural University, Harbin 150030, China
2 shared publications - Ming Jiang
Biopharmaceutical Lab, College of Life Science, Northeast Agricultural University, Harbin 150030, China
2 shared publications - Wenying Sun
Southern Methodist University,Dallas,USA
2 shared publications - Xiangxiang Wang
Biopharmaceutical Lab, College of Life Science, Northeast Agricultural University, Harbin 150030, China
2 shared publications
Latest Publications
- Open Access
- 28 June 2023
- Published by Wiley in Transboundary and Emerging Diseases
- Vol. 2023, 1-16
Development and Evaluation of the Biological Adjuvant Bivalent Vaccine for Preventing Newcastle Disease and Infectious Bursal Disease
Newcastle disease (ND) and infectious bursal disease (IBD) are both one of the most economically important infectious diseases, which cause high infection rate and mortality of chickens and restrict the development of the poultry industry. Currently, vaccination is the most effective method to prevent ND and IBD. In this study, the biological adjuvant bivalent vaccine (rClone30-VP2L-chGM-CSF) was developed for preventing ND and IBD. Furthermore, the immune and protective effects of rClone30-VP2L-chGM-CSF were evaluated in specific-pathogen-free chickens. The experimental results indicated that chickens immunized with rClone30-VP2L-chGM-CSF vaccine significantly improved anti-IBDV and anti-NDV antibody titer; the level of CD4+ T, CD8+ T, B+, MHC-II+, and monocyte/macrophagocyte+ cells; the concentrations of IL-1β, IL-4, IL-17, IFN-α, IFN-β, and IFN-γ; and the splenocyte proliferation rate. Anti-NDV antibody titer reached the theoretical protection value of 4log2 at 7days after immunization in chickens of rClone30-VP2L-chGM-CSF group; however, which at 14days after immunization in chickens of rClone30-VP2L and rClone30. These results showed that chickens immunized with rClone30-VP2L-chGM-CSF stimulated stronger immune response than those with the rClone30-VP2L and rClone30. Chickens were challenged with virulent IBDV BC6/85, which were protected in the rClone30-VP2L-chGM-CSF group. Furthermore, IBDV RNA was not measured, and there appeared to be little apoptosis in the bursa of Fabricius in the rClone30-VP2L-chGM-CSF group. Therefore, rClone30-VP2L-chGM-CSF is a promising vaccine candidate against infectious bursal disease virus (IBDV) and newcastle disease virus (NDV), and it provides an idea for developing other poultry vaccines.
- 28 June 2023
- Published by Wiley in Transboundary and Emerging Diseases
- Vol. 2023, 1-16
Open AccessDevelopment and Evaluation of the Biological Adjuvant Bivalent Vaccine for Preventing Newcastle Disease and Infectious Bursal Disease
Newcastle disease (ND) and infectious bursal disease (IBD) are both one of the most economically important infectious diseases, which cause high infection rate and mortality of chickens and restrict the development of the poultry industry. Currently, vaccination is the most effective method to prevent ND and IBD. In this study, the biological adjuvant bivalent vaccine (rClone30-VP2L-chGM-CSF) was developed for preventing ND and IBD. Furthermore, the immune and protective effects of rClone30-VP2L-chGM-CSF were evaluated in specific-pathogen-free chickens. The experimental results indicated that chickens immunized with rClone30-VP2L-chGM-CSF vaccine significantly improved anti-IBDV and anti-NDV antibody titer; the level of CD4+ T, CD8+ T, B+, MHC-II+, and monocyte/macrophagocyte+ cells; the concentrations of IL-1β, IL-4, IL-17, IFN-α, IFN-β, and IFN-γ; and the splenocyte proliferation rate. Anti-NDV antibody titer reached the theoretical protection value of 4log2 at 7days after immunization in chickens of rClone30-VP2L-chGM-CSF group; however, which at 14days after immunization in chickens of rClone30-VP2L and rClone30. These results showed that chickens immunized with rClone30-VP2L-chGM-CSF stimulated stronger immune response than those with the rClone30-VP2L and rClone30. Chickens were challenged with virulent IBDV BC6/85, which were protected in the rClone30-VP2L-chGM-CSF group. Furthermore, IBDV RNA was not measured, and there appeared to be little apoptosis in the bursa of Fabricius in the rClone30-VP2L-chGM-CSF group. Therefore, rClone30-VP2L-chGM-CSF is a promising vaccine candidate against infectious bursal disease virus (IBDV) and newcastle disease virus (NDV), and it provides an idea for developing other poultry vaccines.
- 6 January 2021
- Published by Wiley in Transboundary and Emerging Diseases
- Vol. 68 (6) , 3658-3675
Development and evaluation of a recombinant VP2 neutralizing epitope antigen vaccine candidate for infectious bursal disease virus
Infectious bursal disease (IBD) is one of the most economically important infectious diseases. Currently, vaccination is the most effective method to prevent IBD. Medium‐virulence vaccines can damage the bursa of Fabricius and result in immunosuppression. Therefore, it is essential to develop a safe and effective vaccine against infectious bursal disease virus (IBDV). In this study, the five neutralizing epitopes of the IBDV VP2 protein were confirmed by neutralizing single chain variable fragment antibodies. Then, the neutralizing epitopes antigen (NEA) protein was constructed with five neutralizing epitopes and expressed by pET‐27b. Furthermore, the immune effect and protective immunity of the NEA protein with the following adjuvants were evaluated in specific‐pathogen‐free chickens: oil emulsion adjuvant (OEA), double emulsion adjuvant (DEA), granulocyte‐macrophage colony‐stimulating factor (GM‐CSF) adjuvant, and complete Freund’s adjuvant (CFA). The experimental results demonstrated that chickens immunized with NEA vaccines elicited stronger humoral and/or cellular immune responses and inflammatory responses than those in the NEA protein group. Chickens were protected in OEA, CFA, and GM‐CSF adjuvant groups, which were challenged with virulent IBDV BC6/85. Furthermore, IBDV RNA was not measured, and there appeared to be little apoptosis in the bursa of Fabricius based on TUNEL histology and the expression of Bax and Bcl‐2 in the OEA, CFA, and GM‐CSF adjuvant groups. Based on the experimental results, the advantages and disadvantages of adjuvants, and industrial production methods, GM‐CSF was found to be the optimal adjuvant. Therefore, NEA with GM‐CSF adjuvant is a promising vaccine candidate against IBDV, and it provides a framework for developing other vaccines against infectious viral diseases.
- 6 January 2021
- Published by Wiley in Transboundary and Emerging Diseases
- Vol. 68 (6) , 3658-3675
Development and evaluation of a recombinant VP2 neutralizing epitope antigen vaccine candidate for infectious bursal disease virus
Infectious bursal disease (IBD) is one of the most economically important infectious diseases. Currently, vaccination is the most effective method to prevent IBD. Medium‐virulence vaccines can damage the bursa of Fabricius and result in immunosuppression. Therefore, it is essential to develop a safe and effective vaccine against infectious bursal disease virus (IBDV). In this study, the five neutralizing epitopes of the IBDV VP2 protein were confirmed by neutralizing single chain variable fragment antibodies. Then, the neutralizing epitopes antigen (NEA) protein was constructed with five neutralizing epitopes and expressed by pET‐27b. Furthermore, the immune effect and protective immunity of the NEA protein with the following adjuvants were evaluated in specific‐pathogen‐free chickens: oil emulsion adjuvant (OEA), double emulsion adjuvant (DEA), granulocyte‐macrophage colony‐stimulating factor (GM‐CSF) adjuvant, and complete Freund’s adjuvant (CFA). The experimental results demonstrated that chickens immunized with NEA vaccines elicited stronger humoral and/or cellular immune responses and inflammatory responses than those in the NEA protein group. Chickens were protected in OEA, CFA, and GM‐CSF adjuvant groups, which were challenged with virulent IBDV BC6/85. Furthermore, IBDV RNA was not measured, and there appeared to be little apoptosis in the bursa of Fabricius based on TUNEL histology and the expression of Bax and Bcl‐2 in the OEA, CFA, and GM‐CSF adjuvant groups. Based on the experimental results, the advantages and disadvantages of adjuvants, and industrial production methods, GM‐CSF was found to be the optimal adjuvant. Therefore, NEA with GM‐CSF adjuvant is a promising vaccine candidate against IBDV, and it provides a framework for developing other vaccines against infectious viral diseases.